These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24370956)

  • 1. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer.
    Wu X; Li D; Liu L; Liu B; Liang H; Yang B
    Arch Gynecol Obstet; 2014 Jun; 289(6):1309-14. PubMed ID: 24370956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
    Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
    Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
    Zou L; He X; Zhang JW
    Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer.
    Wang B; Yu L; Yang GZ; Luo X; Huang L
    Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of serum mesothelin in malignant and benign ovarian masses.
    Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
    Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
    Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
    Lv XL; Zhu Y; Liu JW; Ai H
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.
    Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L
    Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients.
    Bastani A; Asghary A; Heidari MH; Karimi-Busheri F
    Eur J Gynaecol Oncol; 2017; 38(3):418-424. PubMed ID: 29693884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.
    Ning L; Lang J; Wu L
    BMC Cancer; 2022 Jan; 22(1):6. PubMed ID: 34980005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
    Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
    Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.